Navigation Links
Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
Date:11/28/2008

Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Toronto, ON (PRWEB) November 28, 2008 - Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Therapure Biopharma will apply experience gained previously in the production of Biomedical Frontiers' deferoxamine conjugates, which are injectable iron-binding drugs used to neutralize iron build-up in the blood of patients with an iron overload disorder. Biomedical Frontiers believes that their product offers advantages over existing treatments for thalassemia that will result in improved patient compliance and therefore better clinical outcomes.

In addition to manufacturing clinical trial supplies, Therapure Biopharma will provide debt financing that will partially support Biomedical Frontiers' Phase II clinical program for the product. The contract also gives Therapure Biopharma long-term commercial manufacturing rights when the product is approved by regulators.

"Production of this compound for Biomedical Frontiers is a great example of the flexibility of our modern biomanufacturing facility," said Thomas Wellner. "We are able to produce the necessary supplies of their compound quickly to support the continuing clinical development of this important new product."

"We previously contracted with Therapure Biopharma in the manufacture of drug material to support our successful devel
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Biopharmaceutical manufacturers,responsible for an extensive repertoire ... and vaccines -- are faced with,many aspects ... product being assessed. A,new whitepaper from Microtest ... requirements associated with the aseptic processing of,a ...
... FRANCISCO, Aug. 12 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ... for the treatment of cardiovascular disease, announced today that,James ... of VIA,will present a company update at the Fourth ... Tuesday, August 19, 2008 at the Loews Lake,Las Vegas ...
... Aug. 12 DSM Biologics and MorphoSys,AG ... TecDAX) today,announced the signing of a Biopharmaceutical ... of MOR202. MOR202 is a,fully human HuCAL(R) ... the treatment of multiple myeloma. DSM Biologics ...
Cached Biology Technology:White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product 2VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 3
(Date:4/23/2014)... School of Public Health-Bloomington has bolstered the link between ... strong association between heme iron, found only in meat, ... found that heme iron consumption increased the risk for ... was found between nonheme iron, which is in plant ... The study was published online ahead of print in ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... University of Toronto Scarborough research shows that male black ... virgins a rare example of mate preference by ... UTSC post-doc Emily MacLeod and Maydianne Andrade, a professor ... controlled field studies and the wild that males overwhelmingly ... found male black widows can tell whether a potential ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2
... colleagues have received a National Institutes of Health grant to ... messaging system affect cellular processes. ,Matthew Bennett, ... more than a million dollars over five years to gather ... goal is to create techniques to generate and analyze models ...
... German . Until recent decades the Atlantic ... to present-day Argentina. In the 1970s, after years of deforestation, ... cattle pastures. This study reveals an unexpected aspect of deforestation. ... show that the common practice of slash and burn left ...
... Science Exchange, in partnership with the open-access publisher PLOS ... of the Reproducibility Initiative a new ... their critical research findings. "In the ... a lot of public attention, particularly in the context ...
Cached Biology News:NIH backs Rice University study of delay in gene transcription networks 2Marine research in the Brazilian rainforest 2Marine research in the Brazilian rainforest 3Reproducibility Initiative to increase the value of biomedical research 2Reproducibility Initiative to increase the value of biomedical research 3
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: